echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > New development of trump healthcare: NIH gets another $2 billion to develop precision medicine

    New development of trump healthcare: NIH gets another $2 billion to develop precision medicine

    • Last Update: 2017-05-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: healthcare IT news 2017-05-04 on Sunday, representatives passed the health insurance fund spending bill, and the Democratic Party won The bill states that $50 million will be spent to fight opioid abuse But for insurance companies, the move will not help them to gain a foothold in the affordable healthcare bill market As expected, the bill does not mention the payment of cost sharing reduction (CRS) to insurance companies with congressional fund sharing Insurance companies believe that CRS payment at this stage is very necessary to maintain the stability and integrity of market premiums in the Affordable Care Act (ACA) In addition, the Centers for Disease Control and prevention received $7.3 billion, including grants and transfers of ACA prevention and public health funds, while another $42 million expansion sought to combat the abuse of prescription drugs Health resources and Services Administration , HSRA) received $1.5 million in funding, and plans to create an effective telemedicine center in the suburbs to test the effectiveness of telemedicine services; the Centers for Disease Control and prevention received $6 billion, of which $35 million was spent on emergency funding for the Michigan water crisis in Flint City, and another $394 million was spent on Zika virus prevention and response The National Institutes of Health received another $2 billion, a total of $34 billion, the paper said At present, the research focus of NIH is precision medicine The purpose of developing precision medicine is to make medical decision, practice or product model for patients.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.